Mandate

Vinge is advising Nytida in connection with merger with the Solhaga Group

January 25, 2016

Vinge is advising Nytida, which is part of Ambea, in connection with the merger with Solhagagruppen (the “Solhaga Group”).

Nytida intends to merge with the Solhaga Group. Nytida and the Solhaga Group possess considerable experience and expertise within the fields of functional impairment and the Solhaga Group specializes in the fields of neuropsychiatric and psychiatric impairment and reduced development. Both Nytida and the Solhaga Group conduct operations throughout a large part of Sweden and provide accommodation, schooling, short-term accommodation and daytime activities. The Solhaga Group also conducts operations in Norway.

Closing of the transaction is subject to the customary approval of the relevant competition authority.

Vinge’s team consisted of, among others, partners Christina Kokko, Jonas Johansson, Louise Brorson Salomon and Marcus Glader together with associates Linda Sengul, Maria Dahlin, Albert Wållgren, Anna-Maria Terzi, Emil Fahlén Godö and Anne Wijkman.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025